"Telepathy," in the context of Neuralink's developments, refers to a brain-computer interface (BCI) technology designed to allow individuals to control devices with their thoughts. Neuralink envisions "Telepathy" as a means for those who have lost the ability to command their bodies to communicate with computers and operate them with a level of dexterity potentially exceeding that of a person with fully functional hands.
As of late 2025, Neuralink has been conducting clinical trials in the US for its "Telepathy" product, with approvals to launch trials in Canada, the UK, and the UAE. The Neuralink app, also named "Telepathy," facilitates the connection between users and the implant, involving device pairing, body mapping, and a calibration phase. Participants in the trials include individuals with spinal cord injuries, ALS, and other conditions causing paralysis. Neuralink aims to expand the technology to enable control of robotic arms, restore tactile sensation, and address speech and hearing impairments. The long-term goal is to develop a "whole brain interface" capable of reading and writing from any part of the brain.
